Testing an Evidence-based Theoretical Model of Imminent (1-year) Fracture Risk in Elderly Women: Results from the Canadian Multicentre Osteoporosis Study (CaMOS)

VPG, in collaboration with Amgen and CaMos, will be presenting a poster entitled: Testing an Evidence-based Theoretical Model of Imminent (1-year) Fracture Risk in Elderly Women: Results from the Canadian Multicentre Osteoporosis Study (CaMOS) at the ASBMR 2017 Annual Meeting, September 8-11, 2017 at the Colorado Convention Center in Denver, Colorado.

Compared to Oral Sumatriptan, AVP-825 Reduces Disability by Relieving Migraine Severity: An Analysis from the COMPASS Study

James S. McGinley, PhD; RJ Wirth, PhD; Dawn C. Buse, PhD; Ken Shulman, DO; Richard B. Lipton, MD (2017). Compared to Oral Sumatriptan, AVP-825 Reduces Disability by Relieving Migraine Severity: An Analysis from the COMPASS Study. Poster (PO-01-045) to be presented at the 18th Congress of the International Headache Society in Vancouver, Canada.